PMID- 36977151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230331
IS  - 2414-6366 (Electronic)
IS  - 2414-6366 (Linking)
VI  - 8
IP  - 3
DP  - 2023 Feb 27
TI  - Systemic Levels of Pro-Inflammatory Cytokines and Post-Treatment Modulation in 
      Tuberculous Lymphadenitis.
LID - 10.3390/tropicalmed8030150 [doi]
LID - 150
AB  - Pro-inflammatory cytokines are potent stimulators of inflammation and immunity 
      and markers of infection severity and bacteriological burden in pulmonary 
      tuberculosis (PTB). Interferons could have both host-protective and detrimental 
      effects on tuberculosis disease. However, their role has not been studied in 
      tuberculous lymphadenitis (TBL). Thus, we evaluated the systemic pro-inflammatory 
      (interleukin (IL)-12, IL-23, interferon (IFN)alpha, and IFNbeta) cytokine levels in TBL, 
      latent tuberculosis (LTBI), and healthy control (HC) individuals. In addition, we 
      also measured the baseline (BL) and post-treatment (PT) systemic levels in TBL 
      individuals. We demonstrate that TBL individuals are characterized by increased 
      pro-inflammatory (IL-12, IL-23, IFNalpha, IFNbeta) cytokines when compared to LTBI and 
      HC individuals. We also show that after anti-tuberculosis treatment (ATT) 
      completion, the systemic levels of pro-inflammatory cytokines were significantly 
      modulated in TBL individuals. A receiver operating characteristic (ROC) analysis 
      revealed IL-23, IFNalpha, and IFNbeta significantly discriminated TBL disease from LTBI 
      and/or HC individuals. Hence, our study demonstrates the altered systemic levels 
      of pro-inflammatory cytokines and their reversal after ATT, suggesting that they 
      are markers of disease pathogenesis/severity and altered immune regulation in TBL 
      disease.
FAU - Kathamuthu, Gokul Raj
AU  - Kathamuthu GR
AUID- ORCID: 0000-0001-5083-4060
AD  - National Institutes of Health-NIRT-International Center for Excellence in 
      Research, Chennai 600 031, India.
AD  - National Institute for Research in Tuberculosis (NIRT), Chennai 600 031, India.
AD  - Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 
      Solna, Sweden.
FAU - Moideen, Kadar
AU  - Moideen K
AD  - National Institutes of Health-NIRT-International Center for Excellence in 
      Research, Chennai 600 031, India.
FAU - Sridhar, Rathinam
AU  - Sridhar R
AD  - Government Stanley Medical Hospital, Chennai 600 001, India.
FAU - Baskaran, Dhanaraj
AU  - Baskaran D
AD  - National Institute for Research in Tuberculosis (NIRT), Chennai 600 031, India.
FAU - Babu, Subash
AU  - Babu S
AD  - National Institutes of Health-NIRT-International Center for Excellence in 
      Research, Chennai 600 031, India.
AD  - Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious 
      Diseases, National Institutes of Health, Bethesda, MD 20892-0425, USA.
LA  - eng
PT  - Journal Article
DEP - 20230227
PL  - Switzerland
TA  - Trop Med Infect Dis
JT  - Tropical medicine and infectious disease
JID - 101709042
PMC - PMC10053505
OTO - NOTNLM
OT  - ELISA
OT  - LTBI
OT  - TBL
OT  - healthy controls
OT  - pro-inflammatory cytokines
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/29 06:00
MHDA- 2023/03/29 06:01
PMCR- 2023/02/27
CRDT- 2023/03/28 15:23
PHST- 2023/01/23 00:00 [received]
PHST- 2023/02/13 00:00 [revised]
PHST- 2023/02/21 00:00 [accepted]
PHST- 2023/03/29 06:01 [medline]
PHST- 2023/03/28 15:23 [entrez]
PHST- 2023/03/29 06:00 [pubmed]
PHST- 2023/02/27 00:00 [pmc-release]
AID - tropicalmed8030150 [pii]
AID - tropicalmed-08-00150 [pii]
AID - 10.3390/tropicalmed8030150 [doi]
PST - epublish
SO  - Trop Med Infect Dis. 2023 Feb 27;8(3):150. doi: 10.3390/tropicalmed8030150.